Entecavir is generally a drug taken by patients with chronic hepatitis B. If the patient’s liver function is normal, he can take the New Crown vaccine while taking entecavir, and such antiviral drugs as entecavir will not affect the effectiveness and safety of the New Crown vaccination. However, for patients with serum transaminases (ALT or AST) ≥ 5 times the upper limit of normal value, or serum total bilirubin ≥ 51 μmol/L, i.e., patients with significant abnormal liver function, vaccination with New Crown vaccine is temporarily not recommended while taking entecavir and can wait for 1-3 months after liver function returns to normal before vaccinating with New Crown vaccine. Different types of hepatitis B patients have different requirements for New Crown vaccination while taking entecavir. If they are chronic hepatitis B virus carriers, they can receive New Crown vaccination regardless of the viral load in their blood. In the case of patients with chronic hepatitis B or even cirrhosis or liver cancer, they can also receive the New Crown vaccine provided that their liver function is normal. In the case of patients with liver failure, the New Crown vaccine cannot be administered regardless of whether and what medications they are taking. In summary, taking medications for hepatitis B will not affect the effectiveness of the New Crown vaccination, so hepatitis B patients do not need to stop taking antiviral drugs such as entecavir when receiving the New Crown vaccination to avoid aggravation of their condition.